Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 28;11(2):341-349.
doi: 10.14218/JCTH.2022.00002. Epub 2022 May 24.

New Staging Model for Radiation-based Hepatocellular Carcinoma Treatment: A National Multicenter Study

Affiliations

New Staging Model for Radiation-based Hepatocellular Carcinoma Treatment: A National Multicenter Study

Ting-Shi Su et al. J Clin Transl Hepatol. .

Abstract

Background and aims: The study aimed to create a new staging model for radiotherapy-based treatment for prognostic hepatocellular carcinoma (HCC) classification.

Methods: The training cohort comprised 658 patients receiving stereotactic body radiotherapy and external validation cohort comprised 533 patients receiving three-dimensional conformal radiotherapy and intensity-modulated radiotherapy. We established a modified staging system as follows: stage I, solitary nodule without macrovascular invasion, or 2-3 nodules no more than 3.0 cm apart, and performance status (PS) 0-2 (Ia: ALBI-1 grade; Ib: ALBI-2 or 3 grade); stage II: 2-3 nodules with any one nodule more than 3.0-cm apart, or ≥4 nodules, and performance status 0-2 (IIa: ALBI-1 grade; IIb: ALBI-2 grade); stage III: macrovascular invasion, regional lymph node metastasis or distant metastasis, and performance status 0-2 (IIIa: ALBI-1 grade; IIIb: ALBI-2 grade); stage IV: performance status 3-4, or performance status 0-2 with ALBI-3 grade. We analyzed long-term overall survival based on different stages.

Results: The staging model showed an excellent ability to discriminate patients according to four stages and seven substages with notably different curves in the training and validation cohort. The median survival decreased from stages I to IV with 63.0 months in stage I (not reached in Ia, and 53.0 months in Ib), 24.0 months in stage II (28.0 months in IIa, and 22.0 months in IIb), 11.0 months in stage III (18.0 months in IIIa, and 9.0 months in IIIb), and less than 9.0 months in stage IV in the training cohort.

Conclusions: The modified staging model may provide an alternative for clinical radiation oncologists.

Keywords: Hepatocellular carcinoma; Overall survival; Radiotherapy; Staging system; Stereotactic body radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest related to this publication.

Figures

Fig. 1
Fig. 1. (A) Four stages in the training cohort; (B) Seven substages in the training cohort.
Fig. 2
Fig. 2. (A) Four stages in the external validation cohort; (B) Six substages in the external validation cohort; (C) Seven substages in the external validation cohort.
Fig. 3
Fig. 3. Time-dependent (months) receiver operating characteristic curves: (A) in the training cohort; (B) in the external validation cohort; (C) in the entire cohort.

Similar articles

Cited by

References

    1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi: 10.1038/s41575-019-0186-y. - DOI - PMC - PubMed
    1. Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) Liver Cancer. 2020;9(6):682–720. doi: 10.1159/000509424. - DOI - PMC - PubMed
    1. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC), Goyang, Korea 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol. 2019;20(7):1042–1113. doi: 10.3348/kjr.2019.0140. - DOI - PMC - PubMed
    1. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RK, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31(13):1631–1639. doi: 10.1200/JCO.2012.44.1659. - DOI - PubMed
    1. Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122(13):2041–2049. doi: 10.1002/cncr.30008. - DOI - PubMed